Chengda Biotechnology released its half-year report for 2024, during which the company achieved revenue of 0.881 billion yuan, a year-on-year increase of 1.08%; the net income attributable to shareholders of the listed company was 0.22 billion yuan, a year-on-year decrease of 33.99%.
成大生物：2024年上半年净利润同比下降33.99%
Chengda Biotechnology: The net income for the first half of 2024 decreased by 33.99% compared to the same period last year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.